Intraductal carcinoma in situ of left breast
ICD-10 D05.12 is a billable code used to indicate a diagnosis of intraductal carcinoma in situ of left breast.
Intraductal carcinoma in situ (DCIS) of the left breast is a non-invasive form of breast cancer characterized by the presence of abnormal cells within the ducts of the breast tissue. These cells have not invaded surrounding breast tissue, which differentiates DCIS from invasive breast cancer. DCIS is often detected through mammography as microcalcifications and may present with no palpable mass. The risk of progression to invasive breast cancer varies, with estimates suggesting that approximately 25-30% of women with untreated DCIS may develop invasive cancer within 10 years. Surveillance protocols typically include regular mammograms and clinical breast exams, with treatment options ranging from lumpectomy and radiation therapy to mastectomy, depending on the extent of the disease and patient preferences. The prognosis for DCIS is generally favorable, but careful monitoring is essential to manage the risk of progression.
Detailed pathology reports, imaging results, and treatment plans.
Diagnosis of DCIS following mammography, treatment planning discussions.
Ensure accurate staging and grading of the carcinoma.
Clear imaging reports indicating findings of DCIS.
Mammography findings leading to biopsy and diagnosis.
Documentation of imaging techniques and findings is crucial.
Performed for treatment of DCIS.
Operative report detailing the procedure and findings.
Oncology specialists should ensure accurate coding of the procedure.
DCIS is a non-invasive condition where abnormal cells are confined to the ducts of the breast, while invasive breast cancer involves the spread of cancerous cells beyond the ducts into surrounding breast tissue.
